# Celanese Corp: financial statements, quarterly

CE · NYSE · CIK 1306830 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ce.md) · [Financials](/companies/ce/financials.md) · [Filings](/companies/ce/filings.md) · [Insiders](/companies/ce/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ce/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,723](/filings/0001306830-24-000184.md) | [2,555 d](/filings/0001306830-26-000031.md) | [2,611](/filings/0001306830-25-000105.md) | [2,651](/filings/0001306830-25-000174.md) | [2,648](/filings/0001306830-25-000225.md) | [2,358 d](/filings/0001306830-26-000031.md) | [2,389](/filings/0001306830-26-000096.md) | [2,532](/filings/0001306830-26-000117.md) | [2,419](/filings/0001306830-25-000225.md) | [2,204 d](/filings/0001306830-26-000031.md) | [2,337](/filings/0001306830-26-000096.md) | [2,752](/filings/0001306830-26-000117.md) |
| Cost of revenue | $m | [2,050](/filings/0001306830-24-000184.md) | [1,962 d](/filings/0001306830-26-000031.md) | [2,057](/filings/0001306830-25-000105.md) | [2,010](/filings/0001306830-25-000174.md) | [2,029](/filings/0001306830-25-000225.md) | [1,832 d](/filings/0001306830-26-000031.md) | [1,915](/filings/0001306830-26-000096.md) | [1,998](/filings/0001306830-26-000117.md) | [1,898](/filings/0001306830-25-000225.md) | [1,781 d](/filings/0001306830-26-000031.md) | [1,869](/filings/0001306830-26-000096.md) | [2,134](/filings/0001306830-26-000117.md) |
| Gross profit | $m | [673](/filings/0001306830-24-000184.md) | [593 d](/filings/0001306830-26-000031.md) | [554](/filings/0001306830-25-000105.md) | [641](/filings/0001306830-25-000174.md) | [619](/filings/0001306830-25-000225.md) | [526 d](/filings/0001306830-26-000031.md) | [474](/filings/0001306830-26-000096.md) | [534](/filings/0001306830-26-000117.md) | [521](/filings/0001306830-25-000225.md) | [423 d](/filings/0001306830-26-000031.md) | [468](/filings/0001306830-26-000096.md) | [618](/filings/0001306830-26-000117.md) |
| Research and development | $m | [32.0](/filings/0001306830-24-000184.md) | [32.0 d](/filings/0001306830-26-000031.md) | [34.0](/filings/0001306830-25-000105.md) | [33.0](/filings/0001306830-25-000174.md) | [32.0](/filings/0001306830-25-000225.md) | [31.0 d](/filings/0001306830-26-000031.md) | [31.0](/filings/0001306830-26-000096.md) | [31.0](/filings/0001306830-26-000117.md) | [31.0](/filings/0001306830-25-000225.md) | [32.0 d](/filings/0001306830-26-000031.md) | [28.0](/filings/0001306830-26-000096.md) | [29.0](/filings/0001306830-26-000117.md) |
| Selling, general and administrative | $m | [244](/filings/0001306830-24-000184.md) | [274 d](/filings/0001306830-26-000031.md) | [265](/filings/0001306830-25-000105.md) | [255](/filings/0001306830-25-000174.md) | [248](/filings/0001306830-25-000225.md) | [263 d](/filings/0001306830-26-000031.md) | [231](/filings/0001306830-26-000096.md) | [214](/filings/0001306830-26-000117.md) | [231](/filings/0001306830-25-000225.md) | [223 d](/filings/0001306830-26-000031.md) | [226](/filings/0001306830-26-000096.md) | [251](/filings/0001306830-26-000117.md) |
| Operating income | $m | [842](/filings/0001306830-24-000184.md) | [237 d](/filings/0001306830-26-000031.md) | [210](/filings/0001306830-25-000105.md) | [250](/filings/0001306830-25-000174.md) | [245](/filings/0001306830-25-000225.md) | [(1,419) d](/filings/0001306830-26-000031.md) | [165](/filings/0001306830-26-000096.md) | [231](/filings/0001306830-26-000117.md) | [(1,275)](/filings/0001306830-25-000225.md) | [93.0 d](/filings/0001306830-26-000031.md) | [214](/filings/0001306830-26-000096.md) | [276](/filings/0001306830-26-000117.md) |
| Interest expense | $m | [178](/filings/0001306830-24-000184.md) | [178 d](/filings/0001306830-26-000031.md) | [169](/filings/0001306830-25-000105.md) | [174](/filings/0001306830-25-000174.md) | [169](/filings/0001306830-25-000225.md) | [164 d](/filings/0001306830-26-000031.md) | [170](/filings/0001306830-26-000096.md) | [177](/filings/0001306830-26-000117.md) | [177](/filings/0001306830-25-000225.md) | [177 d](/filings/0001306830-26-000031.md) | [183](/filings/0001306830-26-000096.md) | [186](/filings/0001306830-26-000117.md) |
| Income tax | $m | [(236)](/filings/0001306830-24-000184.md) | [(580) d](/filings/0001306830-26-000031.md) | [33.0](/filings/0001306830-25-000105.md) | [29.0](/filings/0001306830-25-000174.md) | [61.0](/filings/0001306830-25-000225.md) | [384 d](/filings/0001306830-26-000031.md) | [9.0](/filings/0001306830-26-000096.md) | [(77.0)](/filings/0001306830-26-000117.md) | [(7.0)](/filings/0001306830-25-000225.md) | [(15.0) d](/filings/0001306830-26-000031.md) | [33.0](/filings/0001306830-26-000096.md) | [11.0](/filings/0001306830-26-000117.md) |
| Net income | $m | [951](/filings/0001306830-24-000184.md) | [681 d](/filings/0001306830-26-000031.md) | [121](/filings/0001306830-25-000105.md) | [155](/filings/0001306830-25-000174.md) | [113](/filings/0001306830-25-000225.md) | [(1,925) d](/filings/0001306830-26-000031.md) | [(24.0)](/filings/0001306830-26-000096.md) | [197](/filings/0001306830-26-000117.md) | [(1,357)](/filings/0001306830-25-000225.md) | [19.0 d](/filings/0001306830-26-000031.md) | [44.0](/filings/0001306830-26-000096.md) | [125](/filings/0001306830-26-000117.md) |
| Diluted EPS | $ per share | [8.69](/filings/0001306830-24-000184.md) | not reported | [1.10](/filings/0001306830-25-000105.md) | [1.41](/filings/0001306830-25-000174.md) | [1.03](/filings/0001306830-25-000225.md) | not reported | [(0.22)](/filings/0001306830-26-000096.md) | [1.80](/filings/0001306830-26-000117.md) | [(12.39)](/filings/0001306830-25-000225.md) | not reported | [0.40](/filings/0001306830-26-000096.md) | [1.13](/filings/0001306830-26-000117.md) |
| Basic EPS | $ per share | [8.73](/filings/0001306830-24-000184.md) | not reported | [1.11](/filings/0001306830-25-000105.md) | [1.42](/filings/0001306830-25-000174.md) | [1.03](/filings/0001306830-25-000225.md) | not reported | [(0.22)](/filings/0001306830-26-000096.md) | [1.80](/filings/0001306830-26-000117.md) | [(12.39)](/filings/0001306830-25-000225.md) | not reported | [0.40](/filings/0001306830-26-000096.md) | [1.14](/filings/0001306830-26-000117.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $bn | [5.9](/filings/0001306830-23-000161.md) | [6.2](/filings/0001306830-25-000027.md) | [5.9](/filings/0001306830-24-000098.md) | [5.9](/filings/0001306830-24-000155.md) | [5.7](/filings/0001306830-24-000184.md) | [5.1](/filings/0001306830-26-000031.md) | [5.4](/filings/0001306830-25-000105.md) | [5.7](/filings/0001306830-25-000174.md) | [6.1](/filings/0001306830-25-000225.md) | [5.7](/filings/0001306830-26-000117.md) | [6.0](/filings/0001306830-26-000096.md) | [5.8](/filings/0001306830-26-000117.md) |
| Total assets | $bn | [25.5](/filings/0001306830-23-000161.md) | [26.6](/filings/0001306830-25-000027.md) | [26.0](/filings/0001306830-24-000098.md) | [25.8](/filings/0001306830-24-000155.md) | [25.9](/filings/0001306830-24-000184.md) | [22.8](/filings/0001306830-26-000031.md) | [23.2](/filings/0001306830-25-000105.md) | [23.7](/filings/0001306830-25-000174.md) | [22.2](/filings/0001306830-25-000225.md) | [21.7](/filings/0001306830-26-000117.md) | [21.7](/filings/0001306830-26-000096.md) | [21.4](/filings/0001306830-26-000117.md) |
| Current liabilities | $bn | [3.6](/filings/0001306830-23-000161.md) | [4.1](/filings/0001306830-25-000027.md) | [4.9](/filings/0001306830-24-000098.md) | [4.6](/filings/0001306830-24-000155.md) | [4.2](/filings/0001306830-24-000184.md) | [3.9](/filings/0001306830-26-000031.md) | [2.8](/filings/0001306830-25-000105.md) | [2.8](/filings/0001306830-25-000174.md) | [3.7](/filings/0001306830-25-000225.md) | [3.7](/filings/0001306830-26-000117.md) | [4.3](/filings/0001306830-26-000096.md) | [4.0](/filings/0001306830-26-000117.md) |
| Long-term debt | $bn | [12.3](/filings/0001306830-23-000161.md) | [13.4](/filings/0001306830-25-000027.md) | [13.4](/filings/0001306830-24-000098.md) | [13.0](/filings/0001306830-24-000155.md) | [12.8](/filings/0001306830-24-000184.md) | [12.5](/filings/0001306830-26-000031.md) | [12.6](/filings/0001306830-25-000105.md) | [12.9](/filings/0001306830-25-000174.md) | [12.8](/filings/0001306830-25-000225.md) | [12.6](/filings/0001306830-26-000117.md) | [12.6](/filings/0001306830-26-000096.md) | [12.0](/filings/0001306830-26-000117.md) |
| Current portion of debt | $bn | [1.4](/filings/0001306830-23-000161.md) | [1.4](/filings/0001306830-25-000027.md) | [2.4](/filings/0001306830-24-000098.md) | [2.0](/filings/0001306830-24-000155.md) | [1.6](/filings/0001306830-24-000184.md) | [1.5](/filings/0001306830-26-000031.md) | [0.4](/filings/0001306830-25-000105.md) | [0.3](/filings/0001306830-25-000174.md) | [1.2](/filings/0001306830-25-000225.md) | [1.2](/filings/0001306830-26-000117.md) | [1.7](/filings/0001306830-26-000096.md) | [1.3](/filings/0001306830-26-000117.md) |
| Shareholders' equity | $bn | [6.5](/filings/0001306830-24-000184.md) | [7.1](/filings/0001306830-26-000031.md) | [7.1](/filings/0001306830-25-000105.md) | [7.1](/filings/0001306830-25-000174.md) | [7.2](/filings/0001306830-25-000225.md) | [5.1](/filings/0001306830-26-000031.md) | [5.1](/filings/0001306830-26-000096.md) | [5.3](/filings/0001306830-26-000117.md) | [4.0](/filings/0001306830-25-000225.md) | [4.0](/filings/0001306830-26-000117.md) | [4.1](/filings/0001306830-26-000096.md) | [4.2](/filings/0001306830-26-000117.md) |

- Cash and equivalents: not reported
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [403 d](/filings/0001306830-24-000184.md) | [830 d](/filings/0001306830-26-000031.md) | [101](/filings/0001306830-25-000105.md) | [292 d](/filings/0001306830-25-000174.md) | [79.0 d](/filings/0001306830-25-000225.md) | [494 d](/filings/0001306830-26-000031.md) | [37.0](/filings/0001306830-26-000096.md) | [410 d](/filings/0001306830-26-000117.md) | [447 d](/filings/0001306830-25-000225.md) | [252 d](/filings/0001306830-26-000031.md) | [76.0](/filings/0001306830-26-000096.md) | [209 d](/filings/0001306830-26-000117.md) |
| Capital expenditure | $m | [131 d](/filings/0001306830-24-000184.md) | [128 d](/filings/0001306830-26-000031.md) | [137](/filings/0001306830-25-000105.md) | [105 d](/filings/0001306830-25-000174.md) | [88.0 d](/filings/0001306830-25-000225.md) | [105 d](/filings/0001306830-26-000031.md) | [102](/filings/0001306830-26-000096.md) | [93.0 d](/filings/0001306830-26-000117.md) | [64.0 d](/filings/0001306830-25-000225.md) | [84.0 d](/filings/0001306830-26-000031.md) | [66.0](/filings/0001306830-26-000096.md) | [62.0 d](/filings/0001306830-26-000117.md) |
| Dividends paid | $m | [76.0 d](/filings/0001306830-24-000184.md) | [77.0 d](/filings/0001306830-26-000031.md) | [77.0](/filings/0001306830-25-000105.md) | [77.0 d](/filings/0001306830-25-000174.md) | [76.0 d](/filings/0001306830-25-000225.md) | [77.0 d](/filings/0001306830-26-000031.md) | [3.0](/filings/0001306830-26-000096.md) | [3.0 d](/filings/0001306830-26-000117.md) | [3.0 d](/filings/0001306830-25-000225.md) | [4.0 d](/filings/0001306830-26-000031.md) | [3.0](/filings/0001306830-26-000096.md) | [3.0 d](/filings/0001306830-26-000117.md) |
| Share repurchases | $m | [0.0 d](/filings/0001306830-23-000161.md) | [0.0 d](/filings/0001306830-25-000027.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [109](/filings/0001306830-23-000161.md) | [109](/filings/0001306830-24-000098.md) | [109](/filings/0001306830-24-000155.md) | [109](/filings/0001306830-24-000184.md) | [110](/filings/0001306830-25-000105.md) | [110](/filings/0001306830-25-000174.md) | [110](/filings/0001306830-25-000225.md) | [109](/filings/0001306830-26-000096.md) | [110](/filings/0001306830-26-000117.md) | [110](/filings/0001306830-25-000225.md) | [110](/filings/0001306830-26-000096.md) | [110](/filings/0001306830-26-000117.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 109,748,926 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001306830-26-000117.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.